ORCA Therapeutics B.V. to Start Repeat-Dosing in Phase 1/2a Study of ORCA-010 in Treatment-Naïve Prostate Cancer Patients.
‘s-Hertogenbosch, 7 September 2021.
ORCA Therapeutics B.V. to Start Highest Scheduled Dose in Phase 1/2a Study of ORCA-010 in Treatment-Naïve Prostate Cancer Patients. Consistent Efficacy Data from First Cohort and Start New Indication. Additional funding secured.
‘s-Hertogenbosch, 5 March 2021.
Orca Therapeutics Announces Positive DSMB Review in Phase 1/2a Study of ORCA-010 in Treatment-Naïve Prostate Cancer Patients.
‘s-Hertogenbosch, 15 October 2020.
ORCA-010 SHOWS IMPRESSIVE FIRST-LINE PROSTATE CANCER DATA.
‘s-Hertogenbosch, 16 Juli 2020.
ORCA Therapeutics BV Announces Treatment of First Patient in a Phase I/IIa Study with ORCA-010 in Treatment-Naïve Patients with Localized Prostate Cancer.
‘s-Hertogenbosch, 23 December 2019.
ORCA Therapeutics receives approval from Spanish Interministerial Council of Genetically Modified Organisms to use ORCA-010 in a Phase I/IIa study in treatment-naïve prostate cancer patients.
‘s-Hertogenbosch, 4 December 2019.
ORCA Therapeutics receives approval from Health Canada to initiate a Phase I/IIa study with its oncolytic adenovirus ORCA-010 in treatment-naïve prostate cancer patients.
‘s-Hertogenbosch, 1 July 2019.
June 3-6, 2019
The VIRION consortium held their 2nd year meeting in Schiphol on the 13 and 14 of September. ORCA met with the consortium partners and associated partners to discuss the progress made in the program. The overall program was presented and discussed with the H2020 REA representatives.
The progress of the consortium projects, ESR development program and collaboration was evaluated positively by the partners and REA representatives.